Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 8/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114962 | 0.81 | CCR2 (0.60) | NAAASMN1; SMN2CCR2 | |
| SCHEMBL1114444 | 0.81 | CCR2 (0.60) | NAAASMN1; SMN2CCR2 | |
| SCHEMBL1114670 | 0.81 | CCR2 (0.60) | NAAASMN1; SMN2CCR2 | |
| SCHEMBL1114510 | 0.81 | CCR2 (0.60) | NAAASMN1; SMN2CCR2 | |
| SCHEMBL1114852 | 0.81 | CCR2 (0.60) | NAAASMN1; SMN2CCR2 | |
| SCHEMBL1114672 | 0.81 | CCR2 (0.60) | NAAASMN1; SMN2CCR2 | |
| SCHEMBL1114932 | 0.81 | CCR2 (0.60) | NAAASMN1; SMN2CCR2 | |
| SCHEMBL967534 | 0.80 | MAPK1 (0.55) | NAAAGAAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL1114636 | 0.80 | CCR2 (0.57) | NAAASMN1; SMN2CCR2 | |
| SCHEMBL968142 | 0.80 | MAPK1 (0.55) | NAAAGAAMAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2008-09-18 | — | — | US | claimed |
| EP-2279741-A2 | Caprolactams and their use as anti-inflammatory agents | Cambridge Enterprise Ltd. (GB) | 2011-02-02 | — | — | EP | disclosed |
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| EP-1691814-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005053702-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | SMURF1, SMURF2, PSEN1 | NAAA 3709/4885GAA 1832/4885MAPK1 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.